{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-346894","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2026-08-12T20:16:29+00:00","discovered_at":"2026-08-12T20:18:00.255600+00:00","generated_at":"2026-08-12T20:18:32.565793+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RenovoRx Q2 revenue $909K, up 115% YoY; raises FY2026 guidance to $3.75-4.25M","bullets":["Q2 2026 revenue $909K, up 61% QoQ and 115% YoY; record quarter, 83% of FY2025 total revenue.","FY2026 revenue guidance raised to $3.75-4.25M from $3-4M, implying ~241-286% YoY growth.","21 active commercial cancer centers (+30% from 16 in Q1); 63 in pipeline; Q3 revenue expected to exceed Q2.","Phase III TIGeR-PaC fully enrolled; 78/86 events; completion H1 2027, topline H2 2027.","First RenovoCath use in sarcoma patient; cash $9.5M, sufficient into H2 2027; break-even target Q4 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-346894","json":"https://secwatch.observer/filing/0001193125-26-346894.json","markdown":"https://secwatch.observer/filing/0001193125-26-346894.md","text":"https://secwatch.observer/filing/0001193125-26-346894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000119312526346894/0001193125-26-346894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000119312526346894/rnxt-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:18:32.565793+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}